Company research
IMMUNIC, INC.
CIK 1280776Updated Sep 27, 2026
SecurityIMUX · NASDAQ · equity
Name history
VITAL THERAPIES INC · through Apr 10, 2019
IMUX price & chart
Loading TradingView…
NASDAQ:IMUX on TradingView ↗About the company
Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company’s lead development program, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials for the treatment of relapsing multiple sclerosis, with top-line data expected to be available by the end of 2026. Initiation of an additional Phase 3 clinical trial in progressive MS is expected later in 2026. Vidofludimus calcium has already shown therapeutic potential and a favorable safety and tolerability profile in Phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). The company’s development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building a broader therapeutics platform addressing neurodegenerative and autoimmune diseases. For …
In the news
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update News provided by Immunic, Inc. Nov 13, 2025, 06:30 ET Share this article Share to X Share this article Share to X – Key Data Highlighting Vidofludimus Calcium's Therapeutic Potential in Multiple Sclerosis Presen ↗
Seeking Alpha
Immunic, Inc. (IMUX) Discusses R&D Advances and Future Directions in Relapsing Multiple Sclerosis Transcript ↗
Immunic, Inc. (IMUX) Presents at EFMC Medicinal Chemistry 2026 Basel - Slideshow ↗
Immunic, Inc. (IMUX) Discusses R&D Advances and Future Directions in Relapsing Multiple Sclerosis - Slideshow ↗
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
SCHEDULE 13G/A filing
SCHEDULE 13G/A filing
SCHEDULE 13G/A filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 24,052,000Source | 40,868,000Source | 54,299,000Source | 127,753,000Source |
| Property, Plant and Equipment, NetUSD | 608,000Source | 545,000Source | 466,000Source | 294,000Source |
| GoodwillUSD | — | — | — | 0Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 15,483,000Source | 35,668,000Source | 46,674,000Source | 106,745,000Source |
| Assets, CurrentUSD | 22,869,000Source | 39,332,000Source | 52,534,000Source | 125,864,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,386,000Source | 3,664,000Source | 5,860,000Source | 9,490,000Source |
| Operating Lease, Right-of-Use AssetUSD | 575,000Source | 991,000Source | 1,299,000Source | 1,552,000Source |
| Other Assets, NoncurrentUSD | — | — | 0Source | 43,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 30,725,000Source | 22,439,000Source | 25,368,000Source | 14,069,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 9,000Source | 8,000Source | 4,000Source | 4,000Source |
| Additional Paid in CapitalUSD | 599,241,000Source | 525,611,000Source | 436,060,000Source | 427,925,000Source |
| Retained Earnings (Accumulated Deficit)USD | -608,571,000Source | -511,399,000Source | -410,892,000Source | -317,280,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 2,648,000Source | 4,209,000Source | 3,759,000Source | 3,035,000Source |
| Stockholders' Equity Attributable to ParentUSD | -6,673,000Source | 18,429,000Source | 28,931,000Source | 113,684,000Source |
| Liabilities and EquityUSD | 24,052,000Source | 40,868,000Source | 54,299,000Source | 127,753,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 30,618,000Source | 22,175,000Source | 24,729,000Source | 13,077,000Source |
| Operating Lease, Liability, CurrentUSD | 470,000Source | 740,000Source | 695,000Source | 571,000Source |
| Accounts Payable, CurrentUSD | 10,138,000Source | 7,846,000Source | 5,099,000Source | 4,281,000Source |
| Operating Lease, Liability, NoncurrentUSD | 107,000Source | 264,000Source | 639,000Source | 992,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 18,645,000Source | 12,913,000Source | 18,664,000Source | 7,986,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 168,000Source | 134,000Source | 111,000Source | 77,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 8,863,000Source | 8,527,000Source | 7,102,000Source | 7,929,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 1,237,000Source | 3,145,000Source | 817,000Source | 799,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -85,806,000Source | -84,766,000Source | -70,828,000Source | -65,144,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -161,000Source | -264,000Source | 9,462,000Source | -9,741,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 161,000Source | 264,000Source | 334,000Source | 112,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 65,577,000Source | 74,541,000Source | 1,033,000Source | 95,760,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -20,185,000Source | -11,006,000Source | -60,071,000Source | 19,882,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 15,483,000Source | 35,668,000Source | 46,674,000Source | 106,745,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 205,000Source | -517,000Source | 262,000Source | -993,000Source |
| Additional Financial Items | ||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 0Source | -30,000Source | -523,000Source | -4,757,000Source |
| General and Administrative ExpenseUSD | 21,245,000Source | 18,006,000Source | 16,008,000Source | 15,263,000Source |
| GoodwillUSD | — | — | — | 0Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 32,970,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Investment Income, InterestUSD | 1,040,000Source | 3,390,000Source | 3,075,000Source | 1,041,000Source |
| Net Income (Loss) Attributable to ParentUSD | -97,172,000Source | -100,507,000Source | -93,612,000Source | -120,407,000Source |
| Nonoperating Income (Expense)USD | 6,056,000Source | -2,455,000Source | 5,611,000Source | -919,000Source |
| Operating ExpensesUSD | 103,228,000Source | 98,052,000Source | 99,223,000Source | 119,488,000Source |
| Other Nonoperating Income (Expense)USD | 5,016,000Source | -1,049,000Source | 2,536,000Source | -1,960,000Source |
| Proceeds from Issuance of Common StockUSD | 0Source | 191,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | 0Source | 5,000Source |
| Provision for Loan, Lease, and Other LossesUSD | 497,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -103,228,000Source | -98,052,000Source | -99,223,000Source | -119,488,000Source |
| Other Nonoperating Income (Expense)USD | 5,016,000Source | -1,049,000Source | 2,536,000Source | -1,960,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -97,172,000Source | -100,507,000Source | -93,612,000Source | -120,407,000Source |
| Earnings Per Share, BasicUSD per share | -0.62Source | -1Source | -2.11Source | -3.78Source |
| Earnings Per Share, DilutedUSD per share | -0.62Source | -1Source | -2.11Source | -3.78Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 155,688,030Source | 100,174,766Source | 44,320,050Source | 31,819,006Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 155,688,030Source | 100,174,766Source | 44,320,050Source | 31,819,006Source |
| Additional Financial Items | ||||
| Common Stock, Dividends, Per Share, DeclaredUSD per share | 0Source | 0Source | 0Source | 0Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 168,000Source | 134,000Source | 111,000Source | 77,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 0Source | -30,000Source | -523,000Source | -4,757,000Source |
| General and Administrative ExpenseUSD | 21,245,000Source | 18,006,000Source | 16,008,000Source | 15,263,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 32,970,000Source |
| Income (Loss) Attributable to Parent, before TaxUSD | -97,172,000Source | -100,507,000Source | -93,612,000Source | -120,408,000Source |
| Investment Income, InterestUSD | 1,040,000Source | 3,390,000Source | 3,075,000Source | 1,041,000Source |
| Management Fee ExpenseUSD | 0Source | 1,690,000Source | — | — |
| Nonoperating Income (Expense)USD | 6,056,000Source | -2,455,000Source | 5,611,000Source | -919,000Source |
| Operating ExpensesUSD | 103,228,000Source | 98,052,000Source | 99,223,000Source | 119,488,000Source |
| Research and Development ExpenseUSD | 81,983,000Source | 80,046,000Source | 83,215,000Source | 71,255,000Source |
Filing attachments
e665684_ex99-1.htm · 8-K · 2026-08-11
EX-99.1 3 e665684_ex99-1.htm Immunic Appoints Elena Ridloff to Board of Directors - Appointment Strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise as the Company Approaches Pivotal Phase 3 ENSURE Readout in Relapsing Multiple Sclerosis as well as Potential Regulatory Filings and Commercialization - NEW YORK, August 10, 2026 - Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic d…
Read attachment ↗e665684_ex99-2.htm · 8-K · 2026-08-11
EX-99.2 4 e665684_ex99-2.htm Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness - - Pivotal Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis on Track, with Top-Line Data Expected by End of 2026 - - C…
Read attachment ↗e665514_ex99-1.htm · 8-K · 2026-05-28
EX-99.1 2 e665514_ex99-1.htm Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis - Late-Breaking Poster Introduces New Unified Statistical Analyses for Assessing Confirmed Disability Changes for Trials in Progressive Multiple Sclerosis - - Additional CALLIPER Data Further Highlight Vidofludimus Calcium’s Favorable Safety and Tolerability Profile; Patient-Reported Out…
Read attachment ↗